ArticleAmerican journal of translational research2016
miRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Oral Microbiota Taxa and Pri-miRNA Expression in Bipolar Disorder: A Case-Control Study.Biomolecules · 2025Article
- Integromics profiling of oral carcinoma: exploring the role of miRNAs and circRNAs.Frontiers in oral health · 2025Review
- Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.Cancer gene therapy · 2022Review
- miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.Breast cancer (Dove Medical Press) · 2022Article
- Article
- Noncoding RNAs in oral premalignant disorders and oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- Long Noncoding RNA RC3H2 Facilitates Cell Proliferation and Invasion by Targeting MicroRNA-101-3p/EZH2 Axis in OSCC.Molecular therapy. Nucleic acids · 2020Article
- miRNA-101 Targets TGF-βR1 to Retard the Progression of Oral Squamous Cell Carcinoma.Oncology research · 2020Article
- Advances in CXCR7 Modulators.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Dynamic of miRNA-101a-3p and miRNA-200a during Induction of Osteoblast Differentiation in Adipose-derived Mesenchymal Stem Cells.International journal of molecular and cellular medicine · 2020Article
- A High-Content Screening Approach to Identify MicroRNAs Against Head and Neck Cancer Cell Survival and EMT in an Inflammatory Microenvironment.Frontiers in oncology · 2019Article
- MiR-106a* inhibits oral squamous cell carcinoma progression by directly targeting MeCP2 and suppressing the Wnt/β-Catenin signaling pathway.American journal of translational research · 2018Article
- Prognostic significance of CXCR7 in cancer patients: a meta-analysis.Cancer cell international · 2018Article
- MiR-101: a potential therapeutic target of cancers.American journal of translational research · 2018Review
- A Looking-Glass of Non-coding RNAs in oral cancer.International journal of molecular sciences · 2017Review
- Interaction between MALAT-1, CCR7 and correlated genes in oral squamous cell carcinoma.International journal of clinical and experimental pathology · 2017Article
- MiR-181d functions as a potential tumor suppressor in oral squamous cell carcinoma by targeting K-ras.International journal of clinical and experimental pathology · 2017Article
- The prognostic value of decreased miR-101 in various cancers: a meta-analysis of 12 studies.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miR-101 is significantly downregulated in various human cancers, including oral squamous cell carcinoma (OSCC). However, the role of miR-101 in OSCC has not been elucidated. In this study, miR-101 lowly expressed in OSCC tissues and cell lines compared with that in adjacent normal tissues and human normal oral keratinocyte cells. Bioinformatics analysis predicted that miR-101 could potentially target CX chemokine receptor 7 (CXCR7), a promoter of tumor development, to attenuate OSCC progression. Restoring miR-101 expression in OSCC cells suppressed cell proliferation, invasion, and migration. The ectopic expression of CXCR7 in OSCC cells overexpressing miR-101 restored the proliferation and motility capabilities abolished by miR-101. The inhibitory effects of miR-101 on OSCC growth and metastasis were mimicked by CXCR7 knockdown in vivo. CXCR7 expression was upregulated in OSCC tissues. The high expression level of CXCR7 was negatively correlated with miR-101 level and poor prognosis of patients with OSCC. Overall, miR-101 exerts tumor-suppressive functions by targeting CXCR7, leading to inhibition of OSCC cell growth, invasion, and migration. Hence, miR-101 may be a potential target for OSCC diagnosis and therapeutic applications.
Indexed as
Identifiers
27904690PMC5126332W2965378960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.